Together for Better Fertility Care.
Explore trusted answers to your fertility questions, shared by experienced IVF specialists to help you make informed decisions with confidence.
A 90-day course is a reasonable initial treatment period, and some obese women with PMOS may show improvement in menstrual-cycle regularity during this time. However, response may vary according to BMI and the severity of insulin resistance.
Evidence indicates an inverse relationship between body weight and the ovarian response to inositol; women with a higher BMI may experience a slower or less pronounced response. Therefore, they may require treatment beyond 90 days, together with weight reduction and lifestyle modification
In another study, a similar combination significantly reduced the average cycle length from 51 to 39 days after six months. González et al., 2024
Cystop OD for an initial 90-day course, assess menstrual and metabolic response, and consider continuation—particularly in women with a higher BMI—based on clinical evaluation.
Higher BMI may influence response, but no evidence establishes an exact BMI-specific treatment duration.
No, there is no problem if the patient continues Ovazoa F Softgel after conception (even unknowingly) during early embryo development alongside sexual intercourse. The supplement supports fertility with safe nutrients like antioxidants that generally pose no short-term risks in early pregnancy. Once pregnancy is confirmed, they Can stop &must consult a doctor immediately for personalized guidance.
Ovazoa Reserve is primarily targeted to women above 30 years for support and preservation of available ovarian reserve. In a 25-year-old, it may be considered when there is documented diminished ovarian reserve or relevant risk factors, but it should not be promoted as a routine supplement to increase conception chances.
Melatonin is not known to cause rupture of membranes. It is an antioxidant that protects membranes and tissue from oxidative damage.
Yes, with appropriate medical assessment. NormoFlora may be considered in clinically stable immunocompromised patients under physician supervision; immunocompromised status alone is not an absolute contraindication.
A systematic review of 57 clinical studies in immunocompromised adults reported generally favorable safety outcomes for the probiotics, doses and durations evaluated, including patients with HIV, cancer and critical illness.
NormoFlora contains approximately 10 billion CFU of L. crispatus, L. plantarum, L. jensenii, L. fermentum, L. rhamnosus, L. acidophilus, L. gasseri, L. reuteri and B. bifidum, plus FOS, to support restoration and maintenance of healthy vaginal flora.
Caution is required because rare cases of Lactobacillus bacteremia have been reported, particularly in patients with severe immunosuppression, critical illness, ICU admission, central venous catheters or significant mucosal barrier disruption.
Therefore, patients with profound neutropenia, active sepsis/bacteremia, severe GI disease, critical illness or advanced immunosuppression should receive individual specialist assessment before use.
In stable HIV/immunocompromised patients, available evidence is generally reassuring, but patients with advanced immunosuppression, very low CD4 counts or opportunistic infections require individualized assessment.
Important limitation: General probiotic safety evidence cannot automatically be considered product-specific evidence for NormoFlora; safety may be strain-specific, so exact strain identification and product-specific safety data are desirable.
NormoFlora may be considered in clinically stable immunocompromised patients under the treating physician’s supervision, while high-risk patients require additional caution and specialist assessment.
Ask our AI support assistant your questions about our platform, features, and services.
